Actively Recruiting
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
Led by University of Athens · Updated on 2026-03-13
240
Participants Needed
1
Research Sites
503 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment: * 60 patients treated with a combination of GLP1 analogue and SGLT2 inhibitor ± metformin * 60 patients treated with GLP-1 agonist as a second step after metformin * 60 patients treated with SGLT2 inhibitor as a second step after metformin * 60 patients treated with a combination of insulin and other antidiabetic agents (metformin - DPP4 inhibitors) Individuals will be equal distributed as far as age, gender and body mass index concerned. In addition, patients suffered from kidney disease and retinopathy are excluded.
CONDITIONS
Official Title
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Has type 2 diabetes mellitus
- Has high or very high cardiovascular risk
- Has heart failure with preserved ejection fraction
You will not qualify if you...
- Has type 1 diabetes mellitus
- Has kidney disease
- Has retinopathy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
"Attikon" University General Hospital
Athens, Attica, Greece, 12462
Actively Recruiting
Research Team
I
Ignatios Ikonomidis, Prof.
CONTACT
A
Aimilianos N. Kalogeris, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here